Background. There is no consensus regarding prostate cancer in renal-transplant recipients (RTR). A questionnaire evaluating prostate cancer screening after transplantation and assessing the number, diagnostic modalities, treatment, and outcome of prostate cancer cases was mailed to 22 French renal-transplant centers.
There is some controversy about the incidence of prostate cancer in renal-transplant recipients (RTR). In the Cincinnati Transplant Tumor Registry (CTTR) (1) and in the Australian and New Zealand Transplant Registry (2) (ANZTR) many of the recorded frequent neoplasms in the general population, such as prostate, breast, lung and uterine cancers, show a decreased incidence among transplant recipients. Conversely, in European Nordic countries (3), prostatecancer frequency in transplant recipients is higher. The only means to precisely ascertain the incidence of prostate cancer is to perform systematic screening. Because there is no consensus about screening in both the general population and RTR, there are some difficulties in accurately assessing actual incidence of prostate cancer. Consequently, any comparisons of incidence between the two populations are questionable. Equally important to the incidence of prostate cancer in RTR is the growth of the tumor, given that it impacts treatment and prognosis. Lastly, there is a lack of data about treatment modalities of prostate cancer in RTR. Indeed, immunosuppression and renal-transplant location are known to modify the recommendations applied to the general population.
A questionnaire was mailed to 22 French renal-transplant centers (Renal Transplantation Committee of the French Urological Association). The survey concerned the number of RTR followed up and sociodemographic characteristics, data about prostate cancer in RTR, type of immunosuppression, modalities of diagnosis, cancer staging, treatment, follow-up, and outcome. Other data collected pertained to the screening practices after transplantation for each center. Only patients who first received a prostate-cancer diagnosis after transplantation and were still on immunosuppression with a functioning renal transplant were considered for the study.
In 7 of the 13 centers that responded, prostate cancer screening was carried out after transplantation annually on RTR after the ages of 40 or 50, depending on the center. Modalities of screening were a digital rectal examination (DRE) associated with a prostate specific antigen (PSA) measurement (PSA cutoff value was 4 ng/mL). The 6 other centers only carried out DRE or PSA testing when clinical symptoms occurred. In 1998, 1,680 male RTR (all men seen during the year 1998, exhaustive) came in to these 13 centers for follow-up. Distribution of the RTR, according to their respective ages, was 328 men under 40 years, 1,030 between 40 and 50, and 322 over 50. Fourteen recipients had undergone echo-guided prostate biopsies performed because of an increase in PSA level in 10 cases, abnormal DRE in 1 case, and clinical symptoms in 3 cases. Of these 14 patients, 11 cases of prostate cancer were diagnosed. Annual incidence in 1998 was 0.65%, and age-standardized incidence (French population) was 0.78%. In these centers, 2,338 male RTR (men seen before and during the year 1998, nonexhaustive) were usually followed up, and 28 cases of prostate cancer were diagnosed (prevalence 1%). Prostate cancer was diagnosed because of an increase in PSA levels in 17 cases, abnormal DRE in 2 cases, transurethral resection of the prostate in 5 cases, clinical symptoms in 2 cases, and metastasis in 2 cases. One center had 7 cases and one center had no cases of prostate cancer. Median age was 58 years (range 41-70 years) at transplantation and 63 years (54 -74 years) at diagnosis. Median time between transplantation and diagnosis was 60 months (1-156 months). Median PSA level at diagnosis was 8 ng/mL (1.9 -318). Clinical stage, biopsy, Gleason score, and treatment are presented in Table 1 . Four of 6 patients who were T3-T4 had triple immunosuppressive regimen (cyclosporine, azathioprine, and steroids). Radical prostatectomy was performed in 11 cases (10 cases, either no or unilateral lymphadenectomy). Immunosuppression was unchanged in 18 cases and was decreased by stopping azathioprine in 5 cases. At 18Ϯ12 months mean follow-up, 22 recipients were alive, 16 of which were alive with no evidence of disease (ANED). Seven patients among 12 T1, and 9 patients among 10 T2 were ANED. Among 6 patients with T3-T4, 1 had a disease progression and 2 had died from prostate cancer. Outcome according to Gleason score showed that among 18 patients with a Gleason score below 7, 11 were ANED. Evolution according to treatment modalities is presented in Table 2 .
In our study, the percentage of prostate cancer was 0.65 (11 of 1,680) and appears as one of the highest incidence ever reported. In the last update of the CTTR study registry (1), in 8,566 organ transplant recipients (7,116 kidneys), 154 cases of prostate cancer were reported. Another evaluation performed by Birkeland et al. (3) in Europe who found 11 cases of prostate cancer in 3,323 males, with a standardized incidence ratio of 2.1 (1.1-3.8). Another study (4) reported 7 recipients with prostate cancer from a group of 2,446 RTR. The interpretation of our results had to be compared with the incidence of prostate cancer in France, which was 35 of 100,000 in 1998 (5), and required that some adjustments be calculated more particularly on age population and screening trends.
The incidence of prostate cancer increases after 60 years of age and median age is around 72 (6). To avoid a selection bias with age, we used an age-standardized incidence, and our higher incidence in RTR was not caused by a RTR population older than the French population. This data highlights the importance of using age-standardized incidence to make comparisons. In the same way, we compared our RTR to the CTTR population. The differences in the recipients' ages and ethnic ratio between our RTR and CTTR do not explain our higher observed incidence (1, 4) . Indeed, age and ethnicity were more likely to decrease the incidence of prostate cancer in our population. First, the percentage of men older than 50 who were transplanted during 1999 in the United States was 43% (7), so transplant recipients in the United States are older than those in our study. Second, African Americans, who are at higher risk of prostate cancer, are more numerous in the United States than in Europe.
With respect to screening alone, the calculation of prostate cancer incidence depends more on the existence of screening than do several other types of cancer. Because there is no systematic screening in the general population in the United States and most European countries, any comparison between the general population and RTR is more difficult than for other forms of cancer in RTR. One main characteristic of RTR facilitates the screening and the diagnosis of prostate cancer: although it is not systematic in transplant centers, screening may be more frequent than in the general population of the same age because physicians follow transplant recipients at least once a year, and the opportunity to have DRE or PSA testing done each year is more important. The percentage of positive biopsies in RTR with PSA level above 4 ng/mL (positive predictive value) was very high and highlights the problems of screening modalities in RTR. It might be useful to modify the limit for the realization of biopsies using age-adjusted PSA and associating free-to-total PSA ratio to improve PSA properties (8) and to increase the percentage of localized tumor at diagnosis. Undoubtedly, prostate cancer incidence will be higher if a systematic prostatecancer screening existed with RTR. To our knowledge, only two series, with 18 and 8 cases, respectively, detailing the course of several prostate cancers after renal transplantation have been published (4, 9) . Some results of these two series are found to be close to our findings. Prostate cancer seems to occur earlier in RTR than in the general population. It is difficult to formulate hypotheses because one explanation could be a lead-time and lengthtime bias observed in screened population (8) . Our study showed that with a localized prostate cancer and curative treatment, the first results are encouraging. On the other hand, the evolution of disease in men with prostate cancer metastasis appeared be worse than in general population. This characteristic has been described for other cancers (4) . Is this because of a modification of the tumor growth? These results provide strong evidence to support a systematic screening in RTR.
The impact of immunosuppression on virus-induced cancers in RTR is well known, and immunosuppressive agents such as azathioprine and cyclosporine have been previously identified as being carcinogenic (10) , but this affect is not as clear with prostate cancer. In our study, four of six patients with extracapsular tumor had triple therapy regimen. A reduction of immunosuppression is frequently performed after the diagnosis of prostate cancer, but it is not yet proven that this reduction improves the prognosis. In the metastatic forms, a possible return to hemodialysis, which causes considerable deterioration in quality of life, must be compared with a hypothetical survival benefit.
In conclusion, our incidence of prostate cancer appears to be higher than previously described in RTR or expected in the general population and remains underestimated because the absence of systematic screening. The lower incidence published in previous series may be caused by lack of systematic screening. First results with curative treatment are encouraging and allow us to recommend such systematic screening with DRE and PSA. Limitations of our study are the short follow-up and the retrospective design.
